Baseline characteristics of HBeAg-positive chronic hepatitis B patients with poor response to entecavir
10.3760/cma.j.issn.1003-9279.2019.04.017
- VernacularTitle: 恩替卡韦应答不佳的HBeAg阳性慢性乙型肝炎患者的基线特征研究
- Author:
Qiqi CHEN
1
;
Cheng CHENG
2
;
Jingjing WANG
2
;
Ting ZHANG
2
;
Minghui LI
2
;
Yao XIE
2
Author Information
1. Department of Hepatology Division Peking University Ditan Teaching Hospital, Beijing 100015, China
2. Department of Hepatology Division Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Antiviral;
Entecavir
- From:
Chinese Journal of Experimental and Clinical Virology
2019;33(4):415-418
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the baseline characteristics of HBeAg-positive chronic hepatitis B patients with poor response to entecavir (ETV).
Methods:A retrospective study of 70 patients who were partial virologic responders to ETV in Beijing Ditan Hospital from January 2016 to January 2019 was conducted. Data of HBeAg quantification, HBV DNA quantification, value of alanine amimnotransferase (ALT), total bilirubin (TBIL), albumin (ALB), and creatinine (Cre) levels at baseline and follow-up point were collected. According to HBV DNA level after 48 weeks, patients were divided into high response group (2 log10 IU/ml≤HBV DNA≤3 log10 IU/ml) and low response group (HBV DNA>3 log10 IU/m). The independent sample t test was used to compare the measurement data between the two groups; the χ2 test was used to compare the categorical data between the two groups.
Results:There were significant differences in the level of TBIL between the two groups before initiating the antiviral treatment (P<0.05). The difference of HBV DNA quantification and TBIL decline degree at 12 weeks were statistically significant (P<0.05). Comparison of HBV DNA quantification, ALT level, ALT decline degree and TBIL decline degree at 24 weeks were also statistically significant (P< 0.05).
Conclusions:Baseline TBIL levels, HBV DNA levels and ALT decline degree after 24 weeks are influencing factors that affect the efficiency of antiviral response.
